We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Preventive AF Anticoagulants Still Erroneously Prescribed

By HospiMedica International staff writers
Posted on 26 Jul 2017
A new study shows that many doctors do not heed atrial fibrillation (AF) safety guidelines and still recommend anticoagulants to prevent stroke, even when contraindicated.

Researchers at the University of Birmingham (UB; United Kingdom) conducted a study that included 12 sequential annual cross-sectional analyses of data from 645 general practices across the United Kingdom contributing to the Health Improvement Network (HIN), a large database of electronic primary care records. More...
The study, conducted between 2004 to 2015, included patients with a diagnosis of AF aged 35 years and up and who were and registered in the HIN for at least one year. The outcome measure was prescription of anticoagulant medication.

The results revealed that the proportion of eligible patients with AF who were prescribed anticoagulants increased from 40.1% to 67.2% during the 12-year period, while the proportion of patients without AF contraindications prescribed anticoagulants increased from 42.1% to 67.7%. In patients with a recent history of major bleeding or aneurysm, prescribing rates in patients with AF contraindications rose from 34.8% to 63.2%, suggesting that 38,000 patients at risk in the UK are treated with anticoagulants. The study was published on June 19, 2017, in the British Journal of General Practice.

“Because anticoagulants prevent strokes in people with this type of irregular pulse, GPs are encouraged to prescribe more anticoagulants to those who need them. This has been happening, and it is good news,” said lead author Nicola Adderley, MD, of the UB Institute of Applied Health Research. “But the sting in the tail is that more people who perhaps shouldn’t be on anticoagulants are also taking them. We need to understand the reasons for this and whether patients might come to any harm.”

Oral anticoagulants reduce the risk of thromboembolic events associated with AF, but many high-risk patients do not take them due to contraindications that create an unfavorable risk/benefit profile. AF patients with absolute contraindications to warfarin anticoagulation therapy include those with recent trauma or surgery, thrombocytopenia, hemorrhagic stroke, and alcoholism. Warfarin therapy is also not indicated for low-risk patients.

Related Links:
University of Birmingham


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Vessel Sealing Instrument
ERGOseal
New
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.